Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ITGAL antisense RNA 1 (ITGAL-AS1)
- Target
- ITGAL-AS1
- Molecular classification
- Long non-coding RNA, Antisense RNA
01
Overview
**ITGAL antisense RNA 1 (ITGAL-AS1)** is a long non-coding RNA (lncRNA), also known as RP11-279C4.1, transcribed from the antisense strand near the ITGAL (integrin alpha L) gene[5][7]. As an antisense RNA, ITGAL-AS1 is not a protein-coding receptor, enzyme, transporter, or classical therapeutic target. Rather, it is presumed to function in regulating the expression of nearby or overlapping genes—including potentially ITGAL itself—through epigenetic or transcriptional interference mechanisms common to antisense lncRNAs[4]. Antisense RNAs can modulate gene expression via effects on transcription, mRNA stability, or chromatin structure, though the specific biological processes or disease contexts regulated by ITGAL-AS1 remain poorly characterized[4]. Emerging lncRNA studies suggest that some antisense RNAs (including those overlapping ITGAL) may play roles in cancer cell behavior, but definitive disease associations or drug interactions are not established for ITGAL-AS1 at this time[7].
- Other names
- RP11-279C4.1
02
Mechanism of action
Antisense-mediated transcriptional regulation (acting through cis and/or trans mechanisms to modulate ITGAL or neighboring gene expression)
03
Biological functions
Regulation of gene expression (mainly via antisense mechanisms)Transcriptional interferencePossible involvement in chromatin modification
04
Disease associations
Cancer (notable mentions in glioma and possibly other malignancies, based on related lncRNA studies)
Beyond the preview
Go deeper on ITGAL antisense RNA 1 (ITGAL-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITGAL antisense RNA 1 (ITGAL-AS1).